The state accuses pharmacy-benefit managers Express Scripts and Prime Therapeutics of an arrangement that drove down what pharmacies get paid — by as much as 80% on some drugs.
MIT researchers built a detailed atlas of the striatum — the brain’s hub for movement, habit and reward — pinpointing neuron types uniquely vulnerable in Huntington’s and addiction.
Plozasiran — an injectable that silences a gene controlling fat metabolism — sharply lowered triglycerides and reduced dangerous pancreatitis attacks in severe hypertriglyceridemia.
The long-acting interferon, already used for a related blood cancer, beat an older drug at controlling platelet counts and cutting clot-related events in a Phase 3 trial.
A randomized study testing a longer antiviral course — on the theory that lingering virus drives long Covid — found no clinical benefit, closing off one hoped-for treatment path.
Remibrutinib, a BTK inhibitor, cut relapses and brain lesions versus a widely used oral MS medicine — and appeared to avoid the liver problems that have dogged its drug class.
The TYK2 inhibitor failed all its main and secondary goals in systemic lupus — the latest setback for a drug class that has struggled to crack the disease.
Stryker’s SportSuite Vision overlays scans and arthroscopic images in a surgeon’s field of view — and just guided its first real operation, a hip arthroscopy at Duke.
AD109 — an oral drug aimed at the muscles that keep the airway open — could offer an alternative for the many people who can’t tolerate a CPAP machine.
Long-lived cells that linger in the lungs after flu keep protective T cells on guard — and adding the protein they make supercharged a nasal flu vaccine in mice.
US neurology and headache societies updated their guidance to reflect a wave of CGRP-targeting medicines — the first refresh in over a decade.
Researchers weakened triple-negative breast cancer by blocking one survival protein, then finished it off by blocking the backup pathway — triggering a lethal form of cell death in lab models.